We next sought to determine whether the up-regulation of the two androgen biosynthetic enzyme genes AKR1C3 and CYP11A1 could be the result of direct targeting of ERRα in prostate cancer cells. The gene discussed is ESRRA; the disease is prostate carcinoma.